Does Semaglutide Reduce Heart Failure Risk Regardless of Heart Pump Strength? | Research

The takeaway

Semaglutide significantly reduced cardiovascular mortality by 26% in obese heart failure patients, with benefits seen in reduced ejection fraction.

26%
Reduction in cardiovascular mortality with semaglutide vs. placebo in obese HF patients

What the researchers found

Semaglutide reduced cardiovascular mortality by 26% overall (RR 0.74), with a 34% reduction in HFrEF patients.

Why it matters

This is among the first evidence that GLP-1 receptor agonists may directly reduce cardiovascular death in heart failure patients, not just improve symptoms.

The numbers in context

- 5 RCTs, 6,898 total patients

- Cardiovascular death: 26% reduction (RR 0.74, 95% CI 0.58-0.94, p=0.02)

- HFrEF subgroup: 34% reduction (RR 0.66, p=0.01)

- HFpEF subgroup: 16% reduction (RR 0.84, p=0.37, not significant)

- Quality of life (KCCQ-CSS): improved by 7.72 points (p<0.001)

- 6-minute walk distance: improved by 14.83 meters (p=0.006)

How the study worked

Meta-analysis of 5 randomized controlled trials totaling 6,898 patients, with subgroup analysis by ejection fraction.

Who was studied

N=6,898 obese patients with heart failure (any ejection fraction) from 5 randomized controlled trials comparing semaglutide to placebo.

What this study cannot tell us

Meta-analysis with heterogeneous trial designs. HFpEF benefit did not reach significance. Relatively short follow-up in some trials.

How to read the evidence

Meta-analysis of 5 RCTs provides moderately strong evidence. Individual trial sizes and designs vary.

When this study was published

Published in 2025 with trials through August 2024.

The bigger picture

If confirmed, semaglutide could become a game-changing heart failure therapy, addressing both the obesity driver and cardiovascular outcomes.

Questions still open

Will larger HFpEF-specific trials confirm the mortality benefit?
Is the heart failure benefit independent of weight loss?

Common questions

Can semaglutide help heart failure patients?

This meta-analysis suggests semaglutide may reduce cardiovascular death by 26% in obese heart failure patients and improve symptoms and exercise capacity.

Does the benefit depend on heart pump strength?

The mortality benefit was statistically significant only in patients with reduced ejection fraction. Results in preserved ejection fraction were promising but not conclusive.

Read the original research

Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.

Cardiology in review

View on PubMed ↗Publisher’s paper ↗

Citation

Otmani, Zina; Elsayed, Hazem Ayman; Yassin, Mazen Negmeldin Aly; Saihi, Mohamed Jalil; Aldemerdash, Mohamed A; Alzawahreh, Ahmad; Hassan, Amr; Alahmed, Farouq Bahaa; Gonnah, Ahmed R; Abdelaziz, Ahmed. (2025). Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000000925